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Massachusetts Medical School, Worcester, MA, USA
MicroRNAs (miRNAs) have increasingly been shown to be
involved in human cancer, and interest has grown about the po-
tential use of miRNAs for cancer therapy. miRNA levels are
known to be altered in cancer cells, including in non-small cell
lung cancer (NSCLC), a subtype of lung cancer that is the
most prevalent form of cancer worldwide and that lacks effective
therapies. The let-7miRNA is involved in the regulation of onco-
gene expression in cells and directly represses cancer growth in
the lung. let-7 is therefore a potential molecular target for tumor
therapy. However, applications of RNA interference for cancer
research have been limited by a lack of simple and efﬁcient
methods to deliver oligonucleotides (ONs) to cancer cells. In
this study, we have used in vitro and in vivo approaches to
show that HCC827 cells internalize hydrophobically modiﬁed
let-7b miRNAs (hmiRNAs) added directly to the culture me-
diumwithout the need for lipid formulation.We identiﬁed func-
tional let-7b hmiRNAs targeting theHMGA2mRNA, one of the
let-7 target genes upregulated in NSCLC, and show that direct
uptake in HCC827 cells induced potent and speciﬁc gene
silencing in vitro and in vivo. Thus, hmiRNAs constitute a novel
class of ONs that enable functional studies of genes involved in
cancer biology and are potentially therapeutic molecules.
INTRODUCTION
let-7 encodes a microRNA (miRNA) that targets HMGA2 in lung
cancer.1–6 Lung cancer is responsible for the most cancer-related
deaths for both men and women in the US with an estimated
224,390 new cases and 158,080 deaths from the disease in 2016.7
Regardless of improving survival rates in the last decades, only about
18% of patients are alive 5 years after diagnosis, emphasizing the ur-
gent need for better therapies.
MiRNAs are small non-coding RNAs that control gene expression at
a post-transcriptional step and have important functions in tumori-
genesis1,8,9 (Figure S1). miRNAs are known to be dysregulated in
many types of cancer, and speciﬁc miRNA expression patterns char-
acterize normal versus tumor tissue or differentiated versus poorly
differentiated tumors.8,10–12. Upregulated miRNAs in cancer cells
promote carcinogenesis by attenuating tumor suppressor genes and
are known as oncomiRs (oncogenic miRNAs).13 Alternatively, miR-
NAs with low expression levels in cancer cells that typically halt can-
cer progression by suppression of the expression of oncogenes are
called tumor suppressor miRNAs.14 Silencing highly expressed
miRNA with anti-miRNA (antimiRs or antagomirs) or substituting
tumor suppressor miRNAs with miRNA mimetics has been demon-
strated as a valuable experimental strategy for the treatment of cancer.
In particular, we have shown the let-7 has promise as a tumor sup-
pressor in pre-clinical mouse models of lung cancer.15–17
Therapeutic oligonucleotides (ONs) are an emerging therapeutic alter-
native to treat diseases with known genetic origin—i.e., antisense ONs,
small interfering RNA (siRNA),18miRNAs,11 and aptamers19—and are
revealing themselves as a new class of drugs. Their advantages over con-
ventional drugs include: simple construction, logically achieved based
on sequence data and straightforward screening, short time frame, lead-
ing to drug candidates, and good potency and duration of effect.11
Nonetheless, as this emergingﬁeld has developed in the last two decades
it has become obvious that there are several limitations to overcome
before such RNAi-based drug candidates become a reality.
Problems such as delivery-associated toxicity, poor transfection efﬁ-
ciency, systemic clearance, nonspeciﬁc biodistribution, and degrada-
tion in circulation have delayed the therapeutic potential of
miRNAs.20,21 Perhaps the most challenging concern that is now dealt
with by many academic laboratories and biotech companies is oligo-
nucleotide drug delivery to extrahepatic tissues in the body.22,23 This
major limitation is partly due to the membrane impermeability of
oligonucleotide therapeutics, since there is no passive diffusion of
the ON to most cells and therefore the ON is delivered at a high
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(potentially toxic) dose or needs some directed mechanism by which
it reaches its speciﬁc target. The absence of powerful delivery vehicles
to target tissues outside the liver is now a primary bottleneck in
miRNA-based therapeutics.
Lipid nanoparticles (LNPs) are attractive carriers for the delivery of
nucleic acids due to their protection from nucleases,24,25 and they
have been used for miRNA delivery in vivo.26,27 Most LNP fabrication
favors delivery of miRNAs to liver, but engineering the lipid design of
LNPs has been shown to alter their distribution, granting potent de-
livery to other organs.28,29 Thus, different lipid elements might be
used to enhance miRNA distribution. Indeed, lipid conjugates have
been studied to increase miRNA bioavailability. Attachment of the
ﬁrst-tested lipophilic group, cholesterol (Chol), which interacts with
serum components such as albumen and lipoproteins, increased cir-
culation times and passive accumulation in the liver,30,31 but it al-
lowed distribution to other tissues too, includingmuscle and placenta,
where they produced RNA silencing. Other lipid-conjugated miRNAs
have been explored, including fatty acids and vitamin-conjugated
miRNA, but delivery and potency were only evaluated in liver.32–34
Moreover, there are potential unwanted effects that are the result of
the RNA duplex itself. These include (1) the activation of the immune
response; (2) the incorporation of the passenger strand (sense) into
RISC (RNA-induced silencing complex); (3) the miRNA potentially
silencing genes other than the intended target gene; and (4) circu-
lating time in the tissues. Several chemical modiﬁcations such as
20-ﬂuoro (20-F)35 and 20-O-methyl (20-OMe)1 (Figure 1A) have
been shown to lower such activities, pointing to the beneﬁcial results
of using synthetic RNAmolecules to not only improve biostability but
also to reduce toxicity.
Reducing the loading of the passenger strand to RISC has also been
achieved by a variety of chemical modiﬁcations, some by speciﬁc
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Figure 1. Chemical modifications stabilize let-7b
(A) Modifications of ribose at the 20 position. (B) General
scheme of lipid-conjugated hmiRNAs. Top is the passenger
strand shown 50 to 30. Bottom is the guide strand shown 50
to 30. (C) Stability of 5 mM hmiR-let-7b versus miRNA let-7b
in 50% serum.
miRNA design36 and others by replacing natu-
ral bases with synthetic ones. There are a variety
of nucleotide mimics where the ribose is modi-
ﬁed to increase afﬁnity for the target and/or
increase nuclease resistance (e.g., locked nucleic
acid [LNA]37) or by 50-capping.38,39 The
20-OMe modiﬁcation has been shown to
improve stability, reduce the immune response,
and improve passenger strand RISC incorpora-
tion.40 Moreover, the substitution of only one
non-bridging oxygen of a phosphodiester with
a sulfur atom creates the phosphorothioate link-
age. Not only does the PS linkage protect oligonucleotides from nu-
cleases, but PS oligonucleotides associate with plasma proteins, result-
ing in longer circulation times.41 Recently, fully hydrophobically
modiﬁed siRNA (hsiRNAs) were shown to improve functionality,
while lipid-conjugated hsiRNAs were delivered to a variety of extra-
hepatic tissues.42–45
Here, we examined a novel oligonucleotide design tomimic let-7b and
avoid some of the barriers of miRNA delivery mentioned above. We
show fast internalization of hydrophobically modiﬁed let-7bmiRNAs
(hmiRNAs) in the non-small cell lung cancer (NSCLC) cell line
HCC827 when added directly to the culture medium without lipid
formulation. We analyzed functional let-7b hmiRNAs targeting of
the mRNA of HMGA2,16,46,47 which is one of the genes upregulating
during NSCLC, and show that direct uptake in HCC827 cells leads to
potent and speciﬁc silencing in vitro. In addition, we systematically
evaluated how lipid conjugates affect hmiRNA distribution in vivo.
We synthesized hmiRNAs conjugated to three lipophilic moieties.
We show that lipid conjugates enable miRNA accumulation and pro-
ductive silencing in tumors after subcutaneous injection. Although
most of the injected miRNA accumulates in clearance organs, we
identiﬁed conjugates that enable functional miRNA delivery to lung
tumor cells. The tissue concentrations of miRNA necessary for effec-
tive silencing varied depending on the tissue and lipid construct. Our
ﬁndings provide proof of principle for the development of lipid-
conjugated hmiRNA oligonucleotides as possible therapeutics for
NSCLC.
RESULTS
Synthesis of DCA, EPA, and Cholesterol-hmiR-let-7b
Conjugates
hmiRNA is a symmetric compound composed of a 21-nt modiﬁed
RNA duplex. Nucleotides in the hmiRNA are modiﬁed with
20-OMe or 20-F (Figure 1A, passenger and guide strands) to promote
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stability, and the 30 end of the passenger strand is conjugated to
eicosapentaenoic acid (EPA), docosanoic acid (DCA), or Chol lipid
to promote membrane binding and association. The 50 end of the
passenger strand is conjugated to Cy3 for imaging. The strands
backbone contains hydrophobic phosphorothioate linkages and pro-
motes cellular uptake by a mechanism similar to that of antisense
oligonucleotides. The presence of phosphorothioates, ribose modiﬁ-
cations, and a lipid conjugate contributes to overall hydrophobicity
and is essential for compound stabilization and efﬁcient cellular
internalization.
To evaluate how the structures of lipid conjugates affect miRNA dis-
tribution in vitro and in vivo, we synthesized three hmiRNAs-let-7b
mimics conjugated with naturally occurring lipids, including EPA,
the saturated fatty acid 22:0, DCA, and sterols Chol (Figure 1B).
Each lipid conjugate was covalently attached to the 30 end of the
miRNA passenger strand, which tolerates a range of covalent modiﬁ-
cations.48 The miRNA-let-7b used in these studies was fully chemi-
cally modiﬁed for maximal stability.
To test the stability of hmiR-let-7b as compared to the naked miRNA
let-7b, both sequences were exposed to 50% serum, which mimic the
physiological conditions. miRNA let-7b was highly unstable in the
presence of serum, whereas hmiR-let-7b remained intact for up to
24 h (Figure 1C), suggesting that the modiﬁcations protect the
miRNA mimic from serum nucleases.
hmiRNAs are Efficiently Internalized by HCC827 NSCLC Cells
Here, we evaluated whether hydrophobically modiﬁed miRNAs are
efﬁciently internalized by NSCLC cell lines HCC827 and A549, and
by normal lung cells, AALE.We found that when added to the culture
medium, the Cy3-labeled hmiRNA-cholesterol conjugate was rapidly
internalized into all three cell lines (Figure 2). Cy3-labeled hmiRNA-
Cholestrol was observed in almost every cell in the culture,
A
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Figure 2. hmiR-let-7b-conjugate internalization
(A) Representative images of hmiR-let-7b-conjugate in the HCC827 cell line. (B) Internalization percentage of 0.4 mM hmiR-let-7b conjugates in the HCC827 cell line after
24 h. ***p < 0.005. Statistical analysis by one-way ANOVA was adjusted for multiple comparisons. Size bar: 50 mm. (C) Magnified representative images of a miRNA-let-7b
and hmiRNA-let-7b-Cholesterol-treated cell. (D) Internalization percentage of hmiR-let-7b conjugates in the A549 cell line after 24 h. (E) Internalization percentage of hmiR-
let-7b conjugates in the AALE cell line after 24 h.
www.moleculartherapy.org
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demonstrating efﬁcient and uniform uptake with 73%, 69%, and 51%
for HCC827, A549, and AALE cells, respectively. Internalization of
Cy3-labeled hmiRNA-DCA was observed frequently in the
HCC827 cell line (73%), but less frequently in the normal lung cells
and in A549 cells. The internalization of the EPA conjugate was
more frequent than the naked miRNA-let-7b in all three cell lines,
although this was not signiﬁcant.
hmiR-let-7b-Cholesterol Increases Apoptosis in HCC827 and
A549 Cells
To further investigate the potential tumor suppressor role of hmiR-
let-7b conjugates in HCC827 and A549 cells, we treated cells with
1 mM hmiR-let-7b conjugate and a control hmiRNA non-targeting
control (NTC) for 72 h. hmiRNA-NTC consisted of a double-
strandedmiRNA containing a sequence without any target gene. Cells
A
C
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Figure 3. hmiR-let-7b Conjugates Increase Apoptosis In Vitro
(A) Mean of annexin V+ PI+ from at least three independent experiments at 72 h post-treatment with hmiR let-7b conjugate (DCA, EPA, and Chol) in the HCC827 cell line.
*p < 0.05, analyzed using t test. (B) Representative annexin V and PI scatterplots for HCC827 cells following treatment with hmiR-let-7b conjugates and NTC. Apoptotic cells
were normalized to NTC from each individual experiment. (C) Mean of annexin V+ PI+ from at least three independent experiments at 72 h post-treatment with hmiR let-7b
conjugate (DCA, EPA, and Cholesterol) in A549 cell line. **p < 0.005.
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then were labeled with annexin V-allophycocyanin (APC) and propi-
dium iodide (PI) and analyzed using ﬂow cytometry. A signiﬁcant
increase in apoptosis activity was observed with the cholesterol con-
jugate as compared to control hmiRNA-NTC in HCC827 and A549
cell lines (Figures 3A and 3C). The DCA and EPA conjugates showed
less of an increase of apoptotic cells (Figures 3A and 3C). Represen-
tative scatterplots for hmiR-let-7b conjugates in HCC827 are shown
in Figure 3B.
Delivery of hmiR-let-7b Conjugates Promotes let-7b
Engagement in RISC
To validate the activity of hmiR-let-7b conjugates, we used a func-
tional assay tomonitor RISC/RNAi activity using a let-7 sensor. Lucif-
erase reporter assays were performed in HCC827 cells that express a
luc reporter with perfect let-7 complementary sites in its 30 UTR.
Luciferase ﬂuorescence levels in these cells are thus inversely corre-
lated with let-7 activity. To test whether hmiR-let-7b conjugates pre-
serve their RNAi efﬁciency, HCC827 cells were co-transfected (lipid
mediated) with the luc 30 UTR let-7 sensor together with each conju-
gate separately using Lipofectamine 2000 in a range of concentrations
of 0.5–100 nM. Following 72 h, luciferase activity was measured and
showed a decrease of up to 80% and a dose response with all three
conjugates (Figure 4B). This reduction in luciferase activity was not
observed in untreated cells.
To further test self-delivery (passive delivery) efﬁcacy of the three
conjugates, cells were transfected with the luc 30 UTR let-7 sensor
on the ﬁrst day, and the next day cells were treated with hmiR-let-
7b conjugates (0.25–5 mM). Following 72 h, luciferase activity was
measured and showed a decrease up to 45% and a dose response
with all three conjugates (Figure 4A). Thus, our cell-based experi-
ments indicated a rapid reduction in luciferase activity in hmiR-let-
7b conjugate-treated cells 72 h after treatment regardless of the
method of delivery.
Lipid Conjugates Increase Endogenous let-7 miRNA and
Decrease Its Target Genes In Vitro
To conﬁrm in vitro delivery of miRNA let-7b, we ﬁrst treated HCC827
cells with EPA, DCA, or cholesterol hmiR-let-7b conjugates, and the
levels of miR-let-7b and its target genes were quantiﬁed using quan-
titative real-time PCR. A signiﬁcant increase in let-7b levels following
48 h of treatment was observed compared to the hmiR-NTC conju-
gate-treated cells, with a 2,000-fold change increase for cholesterol
conjugate, 150-fold change increase for EPA, and a 2-fold change in-
crease for DCA (Figure 5A). hmiR-let-7b conjugate delivery was
active and potently downregulated the let-7 target gene HMGA2.
Downregulation of this target gene ranged between 40% and 60%
(Figure 5B). Treatment with a hmiR-NTC had no effect on the
expression levels of the evaluated genes.
HmiR-let-7b Conjugate Distribution In Vivo after Subcutaneous
Injection
We next determined the tissue-target speciﬁcity of the hmiR-let-7b
conjugate in vivo. To this end, immunodeﬁcient (nu/nu) mice bearing
HCC827 tumors were treated with a single subcutaneous injection
(20 mg/kg) of EPA, Cholesterol, DCA, or PBS. Mice were then sacri-
ﬁced 24 h after administration of the conjugates, and tumors/organs
(lung, liver, and spleen) were harvested. The miRNA passenger/sense
strands were labeled at their 50 ends with a Cy3 ﬂuorophore for qual-
itative analysis of tissue sections by ﬂuorescence microscopy. We also
quantiﬁed the absolute concentrations of let-7b guide/antisense strand
in tissue using a peptide nucleic acid (PNA) hybridization assay and
compared levels of miRNA in those tissues with the control group
(qRT-PCR). As expected, conjugated hmiR-let-7b accumulated
mostly in liver and spleen (Figure 6). We observed a clear relationship
between miRNA lipophilicity and the amount of miRNA that accu-
mulated in these tissues. High lipophilic hmiRNAs with DCA and
cholesterol conjugates accumulated to higher levels in liver and spleen
than did the low lipophilic miRNA-EPA conjugate, which accumu-
lated less in the liver or spleen (PNA assay, absolute amount) (Fig-
ure 6A). Although the highest amounts of hmiR-let-7b were detected
in liver and spleen, signiﬁcant amounts of let-7b were detected in the
tumor, with the highest amount with EPA and DCA conjugates
(8 ng miRNA per mg of tissue). The lowest levels of let-7b were in
normal lung tissues. Taken together and as compared to DCA and
Cholesterol conjugates, the hmiR-let-7b-EPA conjugate accumulates
less in liver, spleen, and normal lung tissue and accumulates more
in tumor, making it a potential drug delivery strategy for NSCLC.
Similar results were observed in ﬂuorescence microscopy analysis
(Figure 6B).
EPA-hmiR-let-7b Conjugates Increased the Amount of Tumor
let-7b miRNA and Enabled Functional Gene Silencing In Vivo
To determine whether EPA-conjugated hmiR-let-7b accumulates to
levels sufﬁcient for productive gene silencing, we injected mice subcu-
taneously with EPA-conjugated hmiR-let-7b. We injected the EPA
conjugate at a dose of 20 mg/kg (seven mice per hmiRNA conjugate
[hmiR-let-7b and non-targeting control (NTC), twice a week for
21 days and sacriﬁced the mice 48 h after the last injection. We
measured the amount of let-7b in the tumors by PNA hybridization
assay. Although most of the miRNA was found in the kidney, we
found that the concentration of let-7b in tumor was 250 ng of miRNA
per mg of tissue (Figure 7A). Wemeasured a 3-fold change of miRNA
let-7b levels in tumors relative to hmiRNA-NTC (Figure 7B). Further-
more, the increase of let-7b levels in tumor-bearing mice treated with
Figure 4. Dose Response of HCC827 Cells to hmiR-let-7b Conjugates
Renilla values were measured 72 h after treatment. Data points were normalized to
untreated cells. (A) Passive delivery. (B) Lipid-mediated (lipo2000) delivery. *p <
0.05, **p < 0.005, ****p < 0.0001. Means ± SD. Statistical analysis was by two-way
ANOVA adjusted for multiple comparisons.
www.moleculartherapy.org
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EPA-hmiR-let-7b resulted in 30% downregulation ofHMGA2mRNA
(GAPDH, serving as a control housekeeping gene) (Figure 7C).
hmiRNA-NTC showed no signiﬁcant reduction in target gene expres-
sion, indicating that the observed silencing is due to sequence-speciﬁc
effects rather than the general chemical scaffold.
Effect of EPA-hmiR-let-7b on Tumor Growth and Ki-67
Immunoreactivity
We observed a small but not signiﬁcant change in tumor size be-
tween the treatment and NTC arms of the xenograft experiment
(Figure 8A). In addition, tumor samples from the treatment group
and NTC treatment were examined histologically using standard
H&E staining after OCT (optimal cutting temperature) ﬁxation.
In both treatment and control groups, the histological ﬁndings
did not identify cellular structures signiﬁcantly different between
the groups (Figure S2).
In order to determine whether EPA-hmiR-let-7b is able to reduce the
proliferation in xenograft tumors at 3.5 weeks post-treatment, in this
study, Ki-67 expression was used to detect alterations in cell prolifer-
ation. Tumor sections from the two groups were stained using immu-
nocytochemistry method with Ki-67, a proliferating marker (green),
and Hoechst (blue). The results (Figures 8B and 8C) showed that
EPA-hmiR-let-7b reduced the proliferative condition compared to
the NTC control. As shown in Figure 8B, EPA-hmiR-let-7b decreased
the ratio of Ki-67/Hoechst to 14.21 ± 0.378% of the control treatment
(p < 0.0001). The result revealed that EPA-hmiR-let-7b treatment
decreased the expression of Ki-67 when compared to EPA-hmiR-
let-7b NTC (Figures 8B and 8C). These immunohistochemistry
(IHC) studies suggested that EPA-hmiR-let-7b slowed proliferation
of the tumor cells, but this effect did not result in a signiﬁcant effect
on tumor volume at 3.5 weeks post-treatment.
DISCUSSION
NSCLC represents about 85% of all lung cancers and is mostly diag-
nosed at an advanced stage.49 Overexpression of miRNA mimics in
cancer cells has been known as a potential therapeutic strategy for
the last 10 years, including for lung cancer.15–17,50,51 However, there
are challenges in the translation of miRNAs into clinical applications,
including low stability due to its degradation by endonucleases/exo-
nucleases,52,53 and lack of potent delivery to the cancer cells due to
their negative charges.54 Previous work has revealed that hydrophobic
modiﬁcations to siRNAs improves their stability without a reduction
in their efﬁcacy,55 while lipids are class of molecules that can be used
to improve drug-targeted delivery.56,57
Our research in the present study addresses the potential of a novel
therapeutic approach combining a lipid and hydrophobically modi-
ﬁed let-7b miRNA that can be useful to target NSCLC with silencing
of HMGA2 mRNA. Indeed, the presence of high levels of HMGA2
mRNA has been observed with lung cancer.2,5,6,58,59
A
B
Figure 5. Expression levels of let-7b and HMGA2
(A) The expression level of let-7b-5p in HCC827 48 h post-treatment with miRNA conjugates. Assays were performed in triplicate. miRNA let-7b levels were normalized to
miRNA-423 levels. ****p < 0.001. Means ± SEM are shown. (B) Expression level ofHMGA2 in HCC827 48 h post-treatment with miRNA conjugates. Assays were performed
in triplicate, and HMGA2mRNA was normalized to GAPDHmRNA levels. **p < 0.005, ****p < 0.0001. Means ± SD are shown. Statistical analysis was by two-way ANOVA
adjusted for multiple comparisons
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Here, we show that cell-targeting lipids, which are crucial for miRNA
retention in the body, might be used as a carrier for therapeutic miR-
NAs in vivo. Lipids with different lipophilicity, Cholesterol, EPA, and
DCA were covalently linked56 to let-7b miRNA, a tumor suppressor
miRNA.60 To test sequence speciﬁcity, we also conjugated the same
lipid to NTC miRNA.
A major limitation of RNA-based drugs in vivo is the fast degradation
(few minutes) of natural ribonucleotide in serum or blood. In order to
keep the RNA intact and protect it from degradation, we synthesized
miRNA mimics with 20-F and 20-OMe modiﬁcations. We evaluated
the internalization of three lipid conjugates in three cell lines,
HCC827, A549, and AALE, and found that the Cholesterol conjugate
was internalized in all three cell lines, while the EPA conjugate and
DCA conjugate were less well internalized.
We showed that in vitro in HCC827 cells, hmiR-let-7b (the silencing
moiety with lipid conjugates) preserved their activity, resulting
in high levels of miR-let-7b and silencing of a well-known let-7b
oncogene target, HMGA2. The Cholesteol conjugate appeared to
be best for silencing in vitro. Interestingly, at 1 mM the silencing
for the Cholesterol conjugate was not signiﬁcant even though the
miRNA levels were high. This could be explained by the known
observation that the degree of silencing does not always correlate
with the level of compound accumulation.44 The structure of the
conjugate (EPA, cholesterol, or DCA) may deﬁne productive
silencing by impacting cellular internalization and/or endosomal
escape.
Moreover, we have found that overexpression of hmiR-let-7b-choles-
terol in the target cell lines HCC827 and A549 was correlated with an
increase in apoptotic cells and endogenousmiRNA let-7b, and this com-
pound was again found to be the best candidate in vitro. The AALE cell
line was not tested because of difﬁculty with cell growth, but we can as-
sume that the degree of apoptosis would be less, as the internalization in
this cell line was also less than in the other two cell lines.
Our in vivo biodistribution study with the three lipid conjugates re-
vealed a different result, and hmiR-let-7b-EPA was found to be the
best candidate. Its injection in three mice showed the highest expres-
sion of miRNA let-7b in tumor tissue. With successive subcutaneous
administration of the optimized lipid (EPA)-hmiR-let-7b construct,
we noticed detectable uptake into target HCC827 tumors in vivo.
The injected amount of the lipid-conjugated miRNAs let-7b was
delivered mostly to primary clearance tissues, including liver, kidney,
and spleen. Nevertheless, lipid-miRNA let-7b conjugate delivered to
HCC827 tumor cells was capable of silencing HMGA2 mRNA that
is overexpressed in the disease tumor tissue. Furthermore, hmiR-
let-7b-EPA was able to reduce tumor cell proliferation.
Conclusion
Our study demonstrates that fully hydrophobically modiﬁed miR-
NAs are effective in gene silencing, and thus they might be a useful
chemical compound in therapeutic studies. Direct conjugation of
RNAi to a targeting agent is emerging as a promising alternative
to nanoparticle-based cargoes for selective delivery, especially to
the liver.61,62 However, many lipid delivery approaches attempt to
target tissues other than the liver. We show lipid-targeted delivery
of a miRNA with biologic activity to tumor tissue in vivo as a proof
of concept for future progress of other targeted miRNA-based ther-
apies. Although our studies were in the context of cancer, this appli-
cation can be applied to different ﬁelds of RNA therapeutics by
specifying a safe, effective strategy to deliver functional miRNAs
to target tissues.
MATERIALS AND METHODS
Cell Line
TheHCC827 cell line was obtained fromDr. S. Kobayashi (Beth Israel
Deaconess Medical Center/Harvard Medical School, USA). A549
cells were obtained fromATCC. AALE cells were a gift fromMatthew
Meyerson’s laboratory. Cells were grown in 90% DMEM supple-
mented with 10% fetal bovine serum (FBS) and 1 penicillin/strepto-
mycin solution. Media and supplements were purchased from
A B
Figure 6. MiRNA-let-7b expression in vivo after 24 hours
(A) Quantification of Let-7b antisense strand in liver, spleen, lung, and tumor after 24 h subcutaneously at 20 mg/kg (PNA hybridization assay). (B) Fluorescence images of
Cy3-labeled DCA-, EPA-, and Cholesterol-conjugated miRNAs in liver, lung, spleen, and tumor. Scale bars, 200 mm.
www.moleculartherapy.org
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Thermo Fisher (Waltham, MA, USA). All cells were maintained at
37C in 5% CO2.
Oligonucleotide Synthesis, Deprotection, and Purification
Oligonucleotides were synthesized following standard protocols on a
MerMade 12 (BioAutomation, Irving, TX, USA). Sense strands were
synthesized at 1- or 2-mmol scales on synthesized fatty acid-function-
alized CPG supports.44 Antisense strandswere synthesized at 10-mmol
scales on CPG functionalized with Unylinker (ChemGenes,Wilming-
ton, MA, USA). 20-O-methyl phosphoramidites (ChemGenes, Wil-
mington, MA, USA), 20-ﬂuoro phosphoramidites (BioAutomation,
Irving, TX, USA), Cy3-labeled phosphoramidites (GenePharma,
Shanghai, China), and custom synthesized (E)-vinylphosphonate
phosphoramidites were used.63 Oligonucleotides were removed
from CPG and deprotected using 40% aqueous methylamine, puriﬁed
by high-performance liquid chromatography (HPLC), and desalted by
size-exclusion chromatography. Oligonucleotide purity and identity
were determined by liquid chromatography-mass spectrometry
(LC-MS) analysis on an Agilent 6530 Accurate-Mass Q-TOF LC/
MS (Agilent Technologies, Santa Clara, CA, USA). TheNTC sequence
has the same modiﬁcation and lipids conjugates: antisense, Pi-UPsU
PsAAUCUCUUUACUGAUAUPsAPsU; sense, lipid-CPsAPsUAUA
UCAGUAAAGAGAUUPsAPsA-Cy3 (X, 20-OMe nucleotide; X, 20-F
nucleotide; Ps, phosphothioate).
Live Cell Imaging
To monitor live cell hmiRNA internalization, cells were plated at a
density of 0.2  105 cells per well on a chambered glass-bottom
dish. Imaging was performed in phenol red-free medium (Thermo
Fisher, Waltham, MA, USA). Cells were treated with 0.4 mmol/L
Cy3-labeled hmiRNA, and live cell imaging was performed after
24 h by a Zeiss LSM 880 confocal microscope at the Confocal Imaging
Core of Beth Israel Deaconess Medical Center.
hmiR-let-7b Stability in Serum
miRNA duplex at 0.5 mMwas diluted in 50% FBS with a ﬁnal concen-
tration of 5 mM and incubated at 37C. At the desired time points, an
aliquot from the assay tube was transferred to a fresh tube containing
GreenGlo (5 mL, Thomas Scientiﬁc, Swedesboro, NJ, USA). Samples
were run on 4%–20% PAGE and analyzed by a Bio-Rad camera.
Flow Cytometry Analysis of Apoptosis
Cultured cells were harvested by trypsinization and washed with 1
PBS. For each sample, 1  106 cells were stained with the annexin
V-APC/PI apoptosis detection kit (BD Biosciences, San Jose, CA,
USA) according to the manufacturer’s instructions, and then
analyzed using ﬂuorescence-activated cell sorting (FACS; BD
FACSCanto II, BD Biosciences, CA, USA).
Activity Study in psiCHECK-2 System
The psiCHECK constructs contained a single copy of matched
sequence complementary to the miRNA guide or one copy of a mis-
matched sequence. For testing the activity of miRNA, 1 105 human
HCC827 cells were seeded in 24-well plates. Cells were then incubated
in a 37 ± 1C, 5% CO2 incubator for 24 h. The next day the cells were
transfected with 500 ng of let-7 luciferase reporter, which carries the
wild-type miR-let-7 sequence (Addgene plasmid no. 50827) using
Lipofectamine 2000 reagent, according to the manufacturer’s proced-
ure, and incubated for 24 h at 37 ± 1C and 5% CO2. Following incu-
bation, cells were transfected (using Lipofectamine 2000 reagent) or
treated with hmiRNA conjugates at ﬁnal concentrations ranging
from 0.5 to 100 nM (lipid mediated) or 0.25 to 5 mM (passive delivery)
in a 500-mL ﬁnal volume. Cells were then incubated for 72 h at 37 ±
1C following assessment of Renilla and ﬁreﬂy luciferase activities.
Activities were measured in each of the miRNA-transfected or treated
samples using the Dual-Luciferase assay kit (Promega, catalog no.
E1960) according to the manufacturer’s procedure. Renilla luciferase
activity value was divided by Fireﬂy luciferase activity value for each
sample (normalization).
RNA Isolation and miRNA Expression Analyses Using qPCR
HCC827 derived tumors from Nu/Nu mice (NU-Foxn1nu; Jackson
Laboratory) were collected in tubes and stored at 80C. Tumor
and tissues were ground and placed in 400 mL of TRIzol. 100 mL of
RNA was extracted using a Direct-zol RNA Minirep kit (Zymo
Research) according to the manufacturer’s instructions.
qRT-PCR
Total RNA from the HCC827 cell line or tumors, lungs, livers, and
spleen was isolated using the Direct-zol RNA MiniPrep Plus kit
(Zymo Research) according to the vending company’s instructions.
RNA quantiﬁcation was estimated with a DS-11 spectrophotometer
(DeNovix). For RT-PCR detection of let-7 mRNA target genes,
200–500 ng of RNA was reverse transcribed with a TaqMan miRNA
A B C Figure 7. let-7b and HMGA2 expression levels in
vivo
(A) Quantification of EPA-let-7b miRNA in liver, kidney,
spleen, and tumor after 3.5 weeks subcutaneously at 2
20 mg/kg per week (PNA hybridization assay, n = 7). (B)
qRT-PCR expression of EPA-miR-let-7b-5p expression.
miRNA levels were normalized to miRNA-423 levels. (C)
HMGA2mRNA expression levels in tumors. mRNA levels
were normalized to GAPDHmRNA levels. *p < 0.05, **p <
0.005. Statistical analysis was by two-way ANOVA
adjusted for multiple comparisons
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assay (Applied Biosystems, Foster City, CA, USA) with the following
conditions: 42C for 60 min and 85C for 5 min. For RT-PCR detec-
tion of the let-7b guide strand, 10 ng of puriﬁed RNA was reverse
transcribed using the let-7b TaqMan miRNA assay (Applied Bio-
systems, Foster City, CA, USA) with the following conditions: 42C
for 15 min and 85C for 5 min. Gene and let-7b expression levels
were determined by real-time PCR using Taq polymerase reagents
(Invitrogen) on the LightCycler 480 II (Roche). TaqMan gene expres-
sion assays (Applied Biosystems) were used with the following cycling
conditions: 95C for 1 min (initial denaturation), then 45 cycles of
95C for 5 s, 60C for 30 s. The GAPDH mRNA or miRNA 423
was ampliﬁed as an internal reference. For the in vivo biodistribution
study, levels of let-7b were normalized to mice treated with PBS.
PNA Hybridization Assay
Levels of the hmiRNA guide (antisense) strand in tumor, liver, spleen,
kidney, and lung were measured by a PNA hybridization assay. In this
assay, a fully complementary Cy3-labeled PNA probe was used to hy-
bridize the antisense strand of hmiRNA. Brieﬂy, tumor, liver, spleen,
kidney, and lung samples were lysed and digested in 200 mL of QG
homogenizing solution (catalog no. QG0517; Affymetrix) containing
2 mL of proteinase K (20 mg/mL). SDS was precipitated using 30 mL of
potassium chloride (3 mol/L) per sample and centrifuged at 4,000 g
for 15min. Supernatants were then diluted in 150mL of hybridization
buffer (50 mM Tris, 10% Acetonitril, pH 8.8) containing 33 nM (5
pmol/150 mL of total sample) of Cy3-labeled PNA (PNABio, Thou-
sand Oaks, CA, USA) and transferred to a PCR 96-well plate (catalog
no. AB-0800/W; Thermo Scientiﬁc). Annealing was carried out on a
Bio-Rad C1000 thermal cycler using the following protocol: 90C for
15 min and 50C for 15 min. Plates were then loaded into an Agilent
Technologies 1260 Inﬁnity Quad-pump HPLC system with a 1260
HiP ALS autosampler. Samples were run through a DNAPac
PA100 anion exchange column (Thermo Fisher Scientiﬁc) and de-
tected by a 1260 FLD ﬂuorescent detector. The mobile phase con-
sisted of buffer A (50% water, 50% ACN, 25 mM Tris-HCl
A B
C
Figure 8. HCC827 cell proliferaton in vivo
(A) Tumor volume. (B) The effect of EPA-hmiR-let-7b on
the cell proliferation was investigated by antibody against
Ki-67. Representative images from sections of the treated
tumors are shown. C) Quantification of the intensity of Ki-
67 and Hoechst staining. Images were captured at 20
magnification from at least four randomly selected fields
for each of six independentmice. ****p < 0.0005, analyzed
using a t test. Size bar: 200 mm.
[pH 8.5], and 1 mM EDTA) and buffer B
(800 mMNaClO4 in buffer A). A steep gradient
of buffer B (10%–100% within 2.5 min) was
used for elution of guide strand-PNA hybrids.
The Cy3 signal (550 nm excitation/570 nm
emission) was monitored and recorded, and
peaks were integrated to obtain the area under
the curve (AUC). Final concentrations were as-
certained by correlating AUCs obtained from experimental samples
with a corresponding calibration curve. Calibration curves were
generated by spiking known amounts of the respective hmiRNA con-
jugate into tissue lysates derived from an untreated animal. Spiked
samples for calibration and experimental samples were processed
and analyzed side by side under the same laboratorial conditions.
Tumor Histology and Imaging
Tumor tissues were ﬁxed in OCT. Embedding and sectioning were
processed by the Histology Core of Beth Israel Deaconess Medical
Center (Boston, MA, USA). 4-mm tissue sections were prepared
and stained with Hochest 443300 and Ki-67 antibody according to
standard protocols. Phase-contrast and ﬂuorescent images were ac-
quired on an EVOS FL cell imaging system with a 4, 10, or 20
objective.
Lung Cancer Xenografts, Biodistribution, and Tumor Growth
All mice were maintained at Beth Israel Deaconess Medical Center in
accordance with Institutional Animal Care and Use Committee
guidelines. For single-dose studies, subcutaneous tumors were
induced in female Nu/Nu mice (NU-Foxn1nu; 6 weeks; n = 12). Hu-
man HCC827 NSCLC cells were cultured in DMEMmedia following
standard tissue culture procedures. HCC827 cells were trypsinized,
counted, and subcutaneously injected into the left ﬂank of 6-week-
old nude mice (Jackson Laboratory, Bar Harbor, ME, USA) using
1 106 cells in 100 mL of DMEMwith 50%Matrigel (BD Biosciences,
San Jose, CA, USA) per injection. When tumors reached an average
volume of 500 mm3 (caliper measurements were taken every
2 days, and tumor volume was calculated using the formula V =
length  width2/2), 100 mL of synthetic hmiRNA-let-7b conjugates
was delivered subcutaneously. Mice were sacriﬁced by CO2 inhalation
after 24 h, and tumors, lungs, livers, and spleens were collected and
prepared for histology and RNA isolation. All animal experiments
were performed under an Institutional Animal Care and Use Com-
mittee-approved animal study protocol.
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Statistical Analysis
Data represent the results of three independent experiments. Differ-
ences between groups were analyzed using one-way or two-way
ANOVA analysis and expressed as mean ± SD from at least three
separate experiments. A t test was used to compare between two
groups. For all tests, p < 0.05 was considered to be statistically signif-
icant (*p < 0.05, **p < 0.005, ****p < 0.0001).
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